- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.05. | Tourmaline Bio shares fall on Phase 2 data; Schrödinger cuts staff | ||
| 20.05. | Pfizer buys into PD-1/VEGF competition with 3SBio deal | ||
| 19.05. | Prime Medicine claims 'proof of concept,' but lays off staff in pivot | ||
| 19.05. | Novavax's COVID vaccine gets FDA approval, but with limits | ||
| 19.05. | Regeneron wins bid to buy 23andMe out of bankruptcy | ||
| 19.05. | FDA OKs first blood test to aid Alzheimer's diagnosis | ||
| 19.05. | How regulatory convergence is raising the bar for sterile drug safety-and how West leads the way | ||
| 19.05. | From insight to impact: How eCOAs strengthen trial data quality | ||
| 19.05. | Bridging the data gaps that impact retail and specialty-lite success | ||
| 16.05. | BioMarin to buy rare disease drugmaker Inozyme for $270M | ||
| 16.05. | Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff | ||
| 16.05. | Novo CEO to depart as obesity drugmaker's challenges rise | ||
| 15.05. | A bespoke CRISPR therapy suggests a blueprint for treating 'N-of-1' diseases | ||
| 15.05. | FDA delays approval decision for Biohaven rare disease drug | ||
| 15.05. | Sanofi to pour more than $20B into US drug research and manufacturing | ||
| 15.05. | AbbVie stakes $335M on a startup's RNAi drugs | ||
| 15.05. | Stopping a 'moral obscenity': Senate Judiciary Committee expresses support for PBM reform | ||
| 14.05. | Novo to work with Septerna in hunt for oral obesity drugs | ||
| 14.05. | Bluebird extends deal deadline; Affimed files for insolvency | ||
| 14.05. | GSK to buy liver disease drug for $1.2B | ||
| 13.05. | Women's health faces growing headwinds, despite jump in venture investment | ||
| 13.05. | 5 questions on Trump's plan to lower US drug prices | ||
| 13.05. | Galapagos backtracks on planned split | ||
| 13.05. | iTeos, GSK to shelve TIGIT drug after study setback | ||
| 13.05. | Andrew Witty steps down as UnitedHealth CEO |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .